You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 11, 2025

CLINICAL TRIALS PROFILE FOR INVEGA SUSTENNA


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for Invega Sustenna

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01136772 ↗ A Comparison of Long-acting Injectable Medications for Schizophrenia Completed Duke University Phase 4 2011-03-01 The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs).
NCT01136772 ↗ A Comparison of Long-acting Injectable Medications for Schizophrenia Completed National Institute of Mental Health (NIMH) Phase 4 2011-03-01 The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs).
NCT01136772 ↗ A Comparison of Long-acting Injectable Medications for Schizophrenia Completed University of North Carolina, Chapel Hill Phase 4 2011-03-01 The purpose of this research study is to compare the "real-world" effectiveness of two FDA-approved and widely used long-acting injectable antipsychotic medications (paliperidone palmitate and haloperidol decanoate) in patients with schizophrenia or schizoaffective disorder who are expected to benefit from the improved medication compliance associated with injectable medications. The goal is to evaluate the effects of the medications on outcomes of importance to patients (relapse, symptoms, adverse effects, functioning) as well as policy makers (all of the above plus costs).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Invega Sustenna

Condition Name

Condition Name for Invega Sustenna
Intervention Trials
Schizophrenia 6
Schizoaffective Disorder 3
Neurotransmitter Agents 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Invega Sustenna
Intervention Trials
Schizophrenia 8
Disease 4
Psychotic Disorders 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Invega Sustenna

Trials by Country

Trials by Country for Invega Sustenna
Location Trials
United States 49
Korea, Republic of 2
Bulgaria 1
Philippines 1
Ukraine 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Invega Sustenna
Location Trials
California 6
Florida 4
New Jersey 4
Texas 4
Missouri 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Invega Sustenna

Clinical Trial Phase

Clinical Trial Phase for Invega Sustenna
Clinical Trial Phase Trials
Phase 4 5
Phase 3 2
Phase 1 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Invega Sustenna
Clinical Trial Phase Trials
Completed 7
Terminated 1
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Invega Sustenna

Sponsor Name

Sponsor Name for Invega Sustenna
Sponsor Trials
Luye Pharma Group Ltd. 3
Janssen Korea, Ltd., Korea 2
National Institute of Mental Health (NIMH) 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Invega Sustenna
Sponsor Trials
Industry 10
Other 8
NIH 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

INVEGA SUSTENNA: Clinical Trials, Market Analysis, and Projections

Introduction

INVEGA SUSTENNA, a long-acting injectable antipsychotic medication, has been a significant player in the treatment of schizophrenia and schizoaffective disorder. This article delves into the clinical trials that have established its efficacy, the current market analysis, and projections for its future.

Clinical Trials and Efficacy

The PRIDE Study

One of the most notable clinical trials for INVEGA SUSTENNA is the Paliperidone Palmitate Research In Demonstrating Effectiveness (PRIDE) study. This 15-month prospective, randomized clinical trial compared the efficacy of INVEGA SUSTENNA with commonly prescribed oral antipsychotics in patients with schizophrenia. The study found that INVEGA SUSTENNA delayed relapse significantly longer than oral antipsychotics, with a median time to first treatment failure of 416 days versus 226 days for oral antipsychotics[1][4].

Real-World Context

The PRIDE study was designed to reflect real-world scenarios, including patients with recent incarceration or substance abuse. This approach made the trial more relevant to clinical practice, as it included patient characteristics often excluded from other trials. The primary endpoint was the length of time to the first treatment failure or relapse, which included events such as psychiatric hospitalization, arrest/incarceration, and discontinuation of antipsychotic medication due to inadequate efficacy or safety concerns[1][4].

Safety Profile

The safety profile of INVEGA SUSTENNA was consistent with that of oral paliperidone. Commonly reported adverse events included injection site pain, insomnia, weight increase, akathisia, and anxiety. No new safety issues were observed during the study[1][3].

Dosage and Administration

INVEGA SUSTENNA is administered as an injectable extended-release suspension, available in pre-filled syringes. The recommended starting dose is 150 mg on Day 1 and 100 mg on Day 8, followed by a monthly dose of 75 mg, which can be adjusted based on individual patient tolerability and efficacy. For patients new to paliperidone or risperidone, it is recommended to establish tolerability with oral forms before initiating INVEGA SUSTENNA[3].

Market Analysis

Current Pricing

As of December 2024, the average retail cost of INVEGA SUSTENNA is approximately $4,089. This cost can vary significantly based on factors such as dosage, geographical location, pharmacy choice, and health insurance coverage[5].

Factors Influencing Cost

  • Dosage: Different dosages have varying price points, making the healthcare provider’s recommendations crucial.
  • Geographical Location: Local economic conditions and healthcare market dynamics affect the cost.
  • Pharmacy Choice: The cost can differ depending on the pharmacy chosen.
  • Health Insurance Coverage: Individuals with insurance that covers this medication may have substantially lower costs[5].

Patent and Generic Competition

Current Patent Protection

INVEGA SUSTENNA is currently protected by four US patents, which contribute to its high retail price. However, these patents are set to expire, paving the way for generic competition[2][5].

Patent Expiration and Generic Competition

The patents for INVEGA SUSTENNA are expected to expire in 2031, which will likely lead to a reduction in the drug's price once generic equivalents become available. The development of generic products involves rigorous testing to demonstrate bioequivalence, which will be crucial for ensuring the quality and efficacy of the generic versions[5].

Impact on Pricing

Historically, the introduction of generic drugs has led to significant price reductions for the original brand-name medications. For example, the entry of generic competitors into the market for other antipsychotic medications has resulted in price reductions of up to 80% or more. It is projected that the price of INVEGA SUSTENNA will decrease substantially by 2031, making the medication more accessible to a broader patient population[5].

Market Dynamics and Patient Adherence

Formulation Advantages

INVEGA SUSTENNA's aqueous suspension formulation avoids gastrointestinal absorption and the first-pass effect, ensuring a controlled drug release rate. This results in lower dose frequency and higher patient adherence rates compared to other antipsychotic medications. Despite the current financial barriers, the unique formulation of INVEGA SUSTENNA can improve adherence rates[4][5].

Financial Barriers and Assistance Programs

The high cost of INVEGA SUSTENNA can impact patient adherence to treatment. However, various assistance programs are available to help mitigate these costs. These programs can make the medication more affordable for patients, especially those without comprehensive health insurance coverage[5].

Projections

Future Accessibility

With the upcoming expiration of its patents and the anticipated entry of generic competitors, INVEGA SUSTENNA is expected to become more accessible to patients. This reduction in cost could lead to increased patient adherence and reduced healthcare burdens[5].

Regulatory Environment

The regulatory environment, including patent protection and approval processes, plays a significant role in the pricing and availability of INVEGA SUSTENNA. As the patents expire, regulatory bodies will need to ensure that generic versions meet the necessary standards for safety and efficacy[5].

Key Takeaways

  • Current Pricing: The average retail cost of INVEGA SUSTENNA is around $4,089 as of December 2024.
  • Factors Influencing Cost: Dosage, geographical location, pharmacy choice, and health insurance coverage affect the cost.
  • Generic Competition: Expected in 2031, which will likely reduce the drug's price.
  • Assistance Programs: Available to help mitigate the high cost.
  • Regulatory Environment: Patent protection and regulatory approval processes impact pricing and availability.

FAQs

What is the primary finding of the PRIDE study on INVEGA SUSTENNA?

The PRIDE study found that INVEGA SUSTENNA delayed relapse significantly longer than oral antipsychotics, with a median time to first treatment failure of 416 days versus 226 days for oral antipsychotics[1][4].

How is INVEGA SUSTENNA administered?

INVEGA SUSTENNA is administered as an injectable extended-release suspension, with a recommended starting dose of 150 mg on Day 1 and 100 mg on Day 8, followed by a monthly dose of 75 mg[3].

What factors influence the cost of INVEGA SUSTENNA?

The cost of INVEGA SUSTENNA is influenced by dosage, geographical location, pharmacy choice, and health insurance coverage[5].

When are the patents for INVEGA SUSTENNA set to expire?

The patents for INVEGA SUSTENNA are set to expire in 2031, which will likely lead to the introduction of generic competitors and a reduction in the drug's price[5].

How does the formulation of INVEGA SUSTENNA impact patient adherence?

The aqueous suspension formulation of INVEGA SUSTENNA ensures a controlled drug release rate, resulting in lower dose frequency and higher patient adherence rates compared to other antipsychotic medications[4][5].

Sources

  1. Janssen Pharmaceuticals, "Study Published in The Journal of Clinical Psychiatry Shows INVEGA SUSTENNA® Effective Six Months Longer Than Common Oral Antipsychotics in Treatment of Schizophrenia," April 15, 2015.
  2. DrugPatentWatch, "INVEGA SUSTENNA Drug Patent Profile."
  3. Health Canada, "Summary Basis of Decision for Invega® Sustenna."
  4. Janssen Pharmaceuticals, "INVEGA SUSTENNA® (paliperidone palmitate) - Comparative Efficacy Study."
  5. DrugPatentWatch, "Pharmaceutical drug prices and trends for INVEGA SUSTENNA."

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.